On-treatment changes in circulating tumor DNA (ctDNA) level as an early predictor of clinical outcome in the LOTUS randomized phase 2 trial of 1st-line ipatasertib (IPAT) + paclitaxel (PAC) for metastatic triple-negative breast cancer (mTNBC) Meeting Abstract
| Authors: | Wongchenko, M. J.; Lipson, D.; Clark, T.; Kennedy, M.; Greene, M.; Breese, V.; Tsiros, A.; Kim, S. B.; Saura, C.; Oliveira, M.; Baselga, J.; Kapp, A. V.; Chan, W. Y.; Singel, S. M.; Gendreau, S.; Dent, R. |
| Abstract Title: | On-treatment changes in circulating tumor DNA (ctDNA) level as an early predictor of clinical outcome in the LOTUS randomized phase 2 trial of 1st-line ipatasertib (IPAT) + paclitaxel (PAC) for metastatic triple-negative breast cancer (mTNBC) |
| Meeting Title: | 109th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 78 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2018 Apr 14-18 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2018-07-01 |
| Language: | English |
| ACCESSION: | WOS:000468819500329 |
| DOI: | 10.1158/1538-7445.Am2018-2964 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2964 -- Source: Wos |
